血浆置换在病毒性呼吸道传染病细胞因子风暴治疗中的作用*

doi:10.3969/j.issn.1671-2587.2020.03.004

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (3): 236-241.DOI: 10.3969/j.issn.1671-2587.2020.03.004

• 新型冠状病毒肺炎专题（一） • 上一篇下一篇

血浆置换在病毒性呼吸道传染病细胞因子风暴治疗中的作用^*

刘奇, 王世春, 姚春艳

400038 重庆,中国人民解放军重庆血站,陆军军医大学第一附属医院输血科

收稿日期:2020-03-30 出版日期:2020-06-20 发布日期:2020-06-13
通讯作者: 姚春艳,女,教授,主任医师,博士,博士研究生导师,主要从事血液安全与临床输血研究,（Tel） 023-68765475（E-mail）yaochunyan@tmmu.edu.cn。
作者简介:刘奇（1992-）,男,助理实验师,学士,主要从事血液制备及保存研究,（E-mail）403578448@qq.com。
基金资助:
*本课题受国家自然科学基金（No.81700180）、青年人才培养计划（No.SWH2018QNKJ-22）资助

Received:2020-03-30 Online:2020-06-20 Published:2020-06-13

摘要/Abstract

摘要： 细胞因子风暴可导致患者单器官或多器官损伤,甚至功能衰竭,是病情恶化的主要原因,早期发现并阻断是逆转病情的关键。目前尚无特异性治疗手段,现有临床数据显示血浆置换在减轻细胞因子风暴治疗中疗效显著,本文结合COVID-19细胞因子风暴发生机制对血浆置换用于包括COVID-19在内的病毒性呼吸道传染疾病治疗进行综述,以期为此类患者行血浆置换治疗提供参考。

关键词: 血浆置换, 细胞因子风暴, 新型冠状病毒肺炎, 冠状病毒, 呼吸道传染疾病

中图分类号:

R457

刘奇, 王世春, 姚春艳. 血浆置换在病毒性呼吸道传染病细胞因子风暴治疗中的作用^*[J]. 临床输血与检验, 2020, 22(3): 236-241.

[1] Yang PH,Ding YB,Xu Z,et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China[J/OL].Medrxiv, (2020-03-03). https://www.medrxiv.org/content/10.1101/2020.02.28.20028068v1.
[2] Pandey PK,Kaul E,Agarwal N,et al.Effectiveness of Therapeutic Plasma Exchange in a Critically Ill Child With Secondary Hemophagocytic Lymphohistiocytosis[J]. Asian J Transfus Sci,2019,13(2):145-147.
[3] Cohen S,Fishman P.Targeting the A₃ Adenosine Receptor to Treat Cytokine Release Syndrome in Cancer Immunotherapy[J]. Drug Des Devel Ther,2019,13:491-497.
[4] Shimabukuro-Vornhagen A,Gödel P,Subklewe M,et al.Cytokine Release Syndrome[J]. J Immunother Cancer,2018,6(1):56.
[5] Jiang H,Yang Z.Severe Recurrent Fever Episodes With Clinical Diagnosis of Hemophagocytic Lymphohistiocytosis, Incomplete Kawasaki Disease and Systemic-Onset Juvenile Idiopathic Arthritis:A Case Report and Literature Review[J]. Front Pediatr,2020,8:93.
[6] Gardner RA,Ceppi F,Rivers J,et al.Preemptive Mitigation of CD19 CAR T-cell Cytokine Release Syndrome Without Attenuation of Antileukemic Efficacy[J]. Blood,2019,134(24):2149-2158.
[7] Giavridis T,van der Stegen SJC,Eyquem J,et al. CAR T Cell-Induced Cytokine Release Syndrome Is Mediated by Macrophages and Abated by IL-1 Blockade[J]. Nat Med,2018,24(6):731-738.
[8] Norelli M,Camisa B,Barbiera G,et al.Monocyte-derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells[J]. Nat Med,2018,24(6):739-748.
[9] Sindel A,Taylor T,Chesney A,et al.Hematopoietic Stem Cell Mobilization Following PD-1 Blockade: Cytokine Release Syndrome After Transplantation Managed With Ascorbic Acid[J]. Eur J Haematol, 2019,103(2):134-136.
[10] Awasthi R,Pacaud L,Waldron E,et al.Tisagenlecleucel Cellular Kinetics, Dose, and Immunogenicity in Relation to Clinical Factors in Relapsed/Refractory DLBCL[J]. Blood Adv,2020,4(3):560-572.
[11] Grazioli A,Athale J,Tanaka K,et al. Perioperative Applications of Therapeutic Plasma Exchange in Cardiac Surgery: A Narrative Review[J/OL]. J Cardiothorac Vasc Anesth, (2020-02-08).https://www.clinicalkey.com/#!/content/journal/1-s2.0-S105307702030118X.
[12] 杨成民,刘进,赵桐茂,主编.中华输血学[M]. 北京:人民卫生出版社,2018:672-691.
[13] Bird L.Calming the Cytokine Storm[J]. Nat Rev Immunol,2018,18(7):417.
[14] Xiaoqiang Chai,Longfei Hu,Yan Zhang, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After2019-nCoV Infection[J/OL].BioRxiv,(2020-02-04). https://www.biorxiv.org/content/10.1101/2020.02.03.931766v1.
[15] Suxin Wan,Qingjie Yi,Shibing Fan,et al. Charact-eristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with2019 novel coronavirus pneumonia (NCP)[J/OL].medRxiv,(2020-02-12). https://www.medrxiv.org/content/10.1101/2020.02.10.20021832v1.
[16] 国家感染性疾病临床医学研究中心, 传染病诊治国家重点实验室. 人工肝血液净化系统应用于重型、危重型新型冠状病毒肺炎治疗的专家共识[J] . 中华临床感染病杂志,2020,13(1): 1-3.
[17] 徐凯进,蔡洪流,沈毅弘,等.2019冠状病毒病(COVID-19)诊疗浙江经验[J/OL].浙江大学学报(医学版):1-12[2020-04-20].http://kns.cnki.net/kcms/detail/33.1248.R.20200222.1417.002.html.
[18] 国家卫生健康委办公厅,国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].(2020-03-03). http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[19] Huang C,Wang Y,Li X,et al.Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China[J]. Lancet,2020,395(10223):497-506.
[20] Jing Liu,Sumeng Li,Jia Liu,et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients[J/OL].medRxiv.(2020-02-22). https://www.medrxiv.org/content/10.1101/2020.02.16.20023671v2.
[21] Jiahua He,Huanyu Tao,Yumeng Yan,et al. Molecular mechanism of evolution and human infection with the novel coronavirus(2019-nCoV)[J/OL]. biorxiv,(2020-02-21).https://www.biorxiv.org/content/10.1101/2020.02.17.952903v1.
[22] Yonggang Zhou,Binqing Fu,Xiaohu Zheng,et al. Aberrant pathogenic GM-CSF + T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus[J/OL]. biorxiv,(2020-02-20).https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1.
[23] 骆嵩,杨丽娟,王春,等.血浆置换和托珠单抗治疗六例2019冠状病毒病(COVID-19)重型患者临床分析[J/OL].浙江大学学报(医学版):1-6[2020-04-20].http://kns.cnki.net/kcms/detail/33.1248.R.20200317.1146.002.html.
[24] Cooper CL.Pandemic H1N12009 Influenza and HIV:A Review of Natural History, Management and Vaccine Immunogenicity[J]. Curr Opin Infect Dis,2012,25(1):26-35.
[25] Patel P,Nandwani V,Vanchiere J,et al.Use of Therapeutic Plasma Exchange as a Rescue Therapy in 2009 pH1N1 Influenza A--an Associated Respiratory Failure and Hemodynamic Shock[J]. Pediatr Crit Care Med, 2011,12(2):e87-89.
[26] Kain T,Lindsay PJ,Adhikari NKJ,et al. Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome[J/OL]. Emerging Infect Dis,2020,26(6), https://doi.org/10.3201/eid2606.200037.
[27] Koch B,Schult-Dietrich P,Büttner S,et al.Lect-in Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination[J]. Blood Purif,2018,46(2):126-133.
[28] Jacob ST, Crozier I, Fischer WA 2nd, et al. Ebola virus disease[J].Nat Rev Dis Primers,2020,6(1):13.
[29] Büttner S,Koch B,Dolnik O,et al.Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease--First Experience With Lectin Affinity Plasmapheresis[J]. Blood Purif,2014,38(3-4):286-291.
[30] Yang X,Yu Y,Xu J,et al. Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study[J/OL]. Lancet Respir Med,2020, https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(20)30079-5.
[31] Xu Z,Shi L,Wang Y,et al.Pathological Findings of COVID-19 Associated With Acute Respiratory Distress Syndrome[J]. Lancet Respir Med,2020, 8(4):420-422.
[32] Tsang K,Zhong NS.SARS:Pharmacotherapy[J]. Respirology,2003,8(Suppl):S25-S30.
[33] 菅宏蕴,周再生,欧秀燕,等.血浆置换联合连续性静脉-静脉血液滤过对急性呼吸窘迫综合征治疗的临床观察[J].中国实用医药,2008,3(26):6-8.
[34] Navarro-Martínez R,Cauli O.Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer's Disease and Chronic Progressive Multiple Sclerosis: A Review[J]. Pharmaceuticals , 2020, 13(2) : 28.
[35] Hall MW,Knatz NL,Vetterly C,et al.Immunoparalysis and Nosocomial Infection in Children With Multiple Organ Dysfunction Syndrome[J]. Intensive Care Med,2011,37(3):525-532.

血浆置换在病毒性呼吸道传染病细胞因子风暴治疗中的作用^*

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	张媛媛, 应美爱, 潘健, 刘洪涛, 刘潜, 戴帅, 王慧茹, 刘会兰. 血浆置换在ABO血型不相容的亲属活体肾移植中应用效果评价^*[J]. 临床输血与检验, 2021, 23(2): 167-172.
[2]	冯子阳, 查占山, 周载鑫, 唐河山, 余咏潮, 钱宝华. 一例血浆置换在马凡综合征患者术后并发血栓性血小板减少性紫癜治疗中的应用[J]. 临床输血与检验, 2021, 23(2): 242-245.
[3]	范亮峰, 陆琼, 姜跃琴, 王中英, 向东. 人血液经56℃孵育处理后溶血率及血型抗原抗体变化^*[J]. 临床输血与检验, 2021, 23(1): 54-60.
[4]	王伟, 奚铭远, 程晨, 许珍珍, 骆群. 血浆置换救治稀料中毒1例[J]. 临床输血与检验, 2021, 23(1): 107-108.
[5]	王娟, 王文婷, 胡兴斌, 尹文. 血浆置换成功治疗难治性莫旺综合征合并膜性肾病1例[J]. 临床输血与检验, 2021, 23(1): 109-111.
[6]	王世春, 阮潜瑛, 刁荣华, 喻荷莲, 戚超, 宋敏, 王珊, 姚春艳. COVID-19流行期间采供血工作特点及对策^*[J]. 临床输血与检验, 2020, 22(5): 454-457.
[7]	杨元铭, 刘姣, 赵真, 王蓉, 张少强, 王海燕. 新冠肺炎疫情期间输血科综合防控措施及效果评价[J]. 临床输血与检验, 2020, 22(5): 470-472.
[8]	庄远, 汪德清. 传统血浆置换治疗如何适应现代医学的发展[J]. 临床输血与检验, 2020, 22(5): 472-476.
[9]	朱鑫方, 王苑, 杜丹心, 夏荣. 康复者恢复期血浆在病毒性疾病治疗中的研究进展[J]. 临床输血与检验, 2020, 22(4): 337-342.
[10]	王云, 赵长城, 谷妍, 姚余有, 刘杨, 岳莉, 石玉如, 查晓丹, 戚应杰. 80例新型冠状病毒感染肺炎患者相关血液检测指标分析[J]. 临床输血与检验, 2020, 22(4): 360-366.
[11]	李营, 张树超, 张少强, 程聪, 王海燕. 康复者血浆治疗新型冠状病毒肺炎疗效分析1例[J]. 临床输血与检验, 2020, 22(4): 366-370.
[12]	曾凡荣, 刘江, 杨光, 王小波, 张洁, 何玢, 朱利杰, 孙梦阳, 余寿杰. 淮南市新型冠状病毒感染病例实验室核酸检测结果分析[J]. 临床输血与检验, 2020, 22(4): 371-375.
[13]	杨俊鸿, 胡文杰, 杨丹蓉, 何涛, 黄霞. 新型冠状病毒肺炎疫情期间献血相关血管迷走神经反应预防措施及监测效果分析[J]. 临床输血与检验, 2020, 22(4): 376-379.
[14]	中国输血协会临床输血管理学委员会. 2019新型冠状病毒肺炎防控期间临床输血血型血清学实验室生物安全防护指南（第二版）^*[J]. 临床输血与检验, 2020, 22(3): 225-228.
[15]	李剑平, 李晓丰, 赵立哲, 王宏阳, 李伟伟, 林园, 刘景汉. 输血相关治疗应用于新冠病毒肺炎救治中的思考^*[J]. 临床输血与检验, 2020, 22(3): 228-232.